The frequency of PI3K/Akt/mTOR (PAM) Pathway mutations in human cancers sparked interest to determine if the pathway is druggable. The modest clinical benefit observed with mTOR rapalogs (temsirolimus and everolimus) provided further motivation to identify additional nodes of pathway inhibition that lead to improved clinical benefit. Akt is a central signaling node of the PAM pathway and could be an ideal target for improved pathway inhibition. Furthermore, inhibitors of Akt may be especially beneficial in tumors with Akt1 mutations. Recently, multiple ATP-competitive Akt inhibitors have been identified and are currently in clinical development. This review details the medicinal chemistry efforts towards identification of these molecules, highlights relevant preclinical data supporting clinical evaluation, and summarizes current clinical development plans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2017.04.090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors.
PLoS One
November 2024
Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
The ALK5 (TGFBR1) receptor serine/threonine kinase transduces TGF-β (Transforming Growth Factor beta) signaling to activate SMAD2/3-dependent and -independent pathways. Here, we aimed to determine the functional consequences of ALK5 mutations in human endometrial cancer (EC). Somatic mutation data were retrieved from publicly available databases.
View Article and Find Full Text PDFThe evolution of small-molecule Akt inhibitors from hit to clinical candidate.
Eur J Med Chem
December 2024
Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China. Electronic address:
Akt, a key regulator of cell survival, proliferation, and metabolism, has become a prominent target for treatment of cancer and inflammatory diseases. The journey of small-molecule Akt inhibitors from discovery to the clinic has faced numerous challenges, with a significant emphasis on optimization throughout the development process. Early discovery efforts identified various classes of inhibitors, including ATP-competitive and allosteric modulators.
View Article and Find Full Text PDFBioinformatics and computational studies of chabamide F and chabamide G for breast cancer and their probable mechanisms of action.
Sci Rep
August 2024
Pharmacy Discipline, Life Science School, Khulna University, Khulna, 9208, Bangladesh.
Article Synopsis
- - The study investigates the potential anticancer effects of two alkaloids, Chabamide F and Chabamide G, derived from a traditional medicinal plant, Piper chaba, particularly focusing on their mechanisms against breast cancer (BC).
- - Using in silico methods, researchers identified 64 BC-related genes and found that key biological pathways, including RAS and PI3K-AKT, are heavily linked to the effects of the alkaloids on tumor growth and spread.
- - Molecular docking suggests that Chabamide F and G have strong binding affinities for critical proteins (SRC and AKT1) involved in breast cancer, indicating potential therapeutic benefits, especially with G showing significantly higher binding energies than control drugs. *
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
J Med Chem
April 2024
Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany.
Article Synopsis
- - Akt kinase plays a crucial role in cell functions such as growth, survival, metabolism, and migration, and its dysregulation is linked to cancer and metabolic disorders.
- - Research into Akt inhibitors aims to counteract overactive Akt signaling, with three main types: ATP-competitive, allosteric, and covalent-allosteric inhibitors, each functioning in different ways to inhibit Akt activity.
- - Capivasertib, an ATP-competitive inhibitor, was recently approved by the FDA for breast cancer treatment, but challenges like selectivity, biomarker identification, and reducing side effects remain, especially for covalent-allosteric inhibitors that show promise for future therapies.
Selectivity Studies and Free Energy Calculations of AKT Inhibitors.
Molecules
March 2024
Department of Chemistry, University of Nebraska at Omaha, Omaha, NE 68182, USA.
Protein kinase B (PKB) or AKT protein is an important target for cancer treatment. Significant advances have been made in developing ATP-competitive inhibitors and allosteric binders targeting AKT1. However, adverse effects or toxicities have been found, and the cutaneous toxicity was found to be linked to the inhibition of AKT2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!